Therapeutic Peptide SS ‐31 Modulates Membrane Binding and Aggregation of α‐Synuclein and Restores Impaired Mitochondrial Function
Chemical Biology & Drug Design · 2026-06 · 107 (6)
DOI: 10.1111/cbdd.70332 ↗At a glance
Journal article in Chemical Biology & Drug Design, published online on 2026-05-31. Written by Ewelina Stefaniak and 5 co-authors. Institution: National Heart and Lung Institute, Imperial College London, Molecular Sciences Research Hub, London, UK. Major MEDLINE topics: alpha-Synuclein, Mitochondria, Oligopeptides. Cited 1 times so far (Crossref); 91 references. The full text is freely available (open access, CC BY 4.0). Funded by: The Leverhulme Trust, Biotechnology and Biological Sciences Research Council, Horizon 2020 Framework Programme.
Abstract (original language)
Membrane binding and aggregation properties of α‐synuclein are closely associated with Parkinson's disease and a class of related syndromes named as synucleinopathy. This study explored the potential of SS‐31 (Elamipretide), a therapeutic tetrapeptide with alternating cationic and aromatic residues and known properties of mitochondrial inner membrane binding and oxidative stress reduction, in modulating α‐synuclein interaction with the lipid membranes and mitigating the impairment of mitochondrial function induced by α‐synuclein oligomers. It was demonstrated by both fluorescence correlation spectroscopy and fluorescence anisotropy that SS‐31 displaces both wild‐type and N‐terminal acetylated α‐synuclein from negatively charged small unilamellar vesicles in a dose‐dependent manner. Thioflavin‐T assay and transmission electron microscopy showed that SS‐31 inhibits membrane‐induced α‐synuclein aggregation and alters the morphology of α‐synuclein fibrils. Moreover, MTT assay and Seahorse Mito Stress Test indicated that SS‐31 enhances cell viability and restores impaired mitochondrial function in α‐synuclein oligomer‐treated neuroblastoma cells. Finally, confocal imaging revealed that SS‐31 hinders cellular uptake of α‐synuclein oligomers, possibly by modifying cell membrane electrostatics. These findings suggest that SS‐31 potentially attenuates α‐synuclein induced mitochondrial impairment via its interaction with the lipid membranes, justifying further development of a peptide‐based intervention against α‐synuclein mediated pathology.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- National Heart and Lung Institute, Imperial College London, Molecular Sciences Research Hub, London, UK.
- Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
- Department of Chemistry, Imperial College London, Molecular Sciences Research Hub, London, UK.
ORCID profiles: Ewelina Stefaniak, Xucheng Yan, Liming Ying
Funding
- The Leverhulme Trust
- Biotechnology and Biological Sciences Research Council
- Horizon 2020 Framework Programme
- Leverhulme Trust
Cite
APA
Stefaniak, E., Cui, B., Yan, X., Sun, K., Teng, X., & Ying, L. (2026). Therapeutic Peptide SS ‐31 Modulates Membrane Binding and Aggregation of α‐Synuclein and Restores Impaired Mitochondrial Function. Chemical Biology & Drug Design, 107(6). https://doi.org/10.1111/cbdd.70332
Vancouver
Stefaniak E, Cui B, Yan X, Sun K, Teng X, Ying L. Therapeutic Peptide SS ‐31 Modulates Membrane Binding and Aggregation of α‐Synuclein and Restores Impaired Mitochondrial Function. Chemical Biology & Drug Design. 2026;107(6). doi:10.1111/cbdd.70332
BibTeX
@article{Stefaniak2026,
author = {Stefaniak, Ewelina and Cui, Beiyuan and Yan, Xucheng and Sun, Kexin and Teng, Xiangyu and Ying, Liming},
title = {Therapeutic Peptide SS ‐31 Modulates Membrane Binding and Aggregation of α‐Synuclein and Restores Impaired Mitochondrial Function},
journal = {Chemical Biology & Drug Design},
year = {2026},
volume = {107},
number = {6},
doi = {10.1111/cbdd.70332}
}
EUVIMED